Epicatechin Gallate

Epicatechin Gallate

SCHEMBL39047

O=C(O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1ccc(O)c(O)c1)c1cc(O)c(O)c(O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 7/20 1.00
BACE1 P56817 5/20 1.00
BCL2 P10415 4/20 1.00
PSMB5 P28074 4/20 1.00
SNCA P37840 4/20 1.00
PGD P52209 4/20 1.00
PKM P14618 3/20 1.00
MET P08581 3/20 1.00
KDM4E B2RXH2 3/20 1.00
MEN1 O00255 3/20 1.00
MAPT P10636 3/20 1.00
RECQL P46063 3/20 1.00
KMT2A Q03164 3/20 1.00
TDP1 Q9NUW8 3/20 1.00
APP P05067 2/20 1.00
ADAMTS4 O75173 2/20 1.00
SLCO2B1 O94956 2/20 1.00
CNR1 P21554 2/20 1.00
CNR2 P34972 2/20 1.00
RAD52 P43351 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Epicatechin Gallate SCHEMBL30977096 1.00 DYRK1A (1.00) DYRK1ABACE1BCL2PSMB5SNCA
Epicatechin Gallate SCHEMBL39046 1.00 DYRK1A (1.00) DYRK1ABACE1BCL2PSMB5SNCA
(-)-Catechingallate SCHEMBL31181360 1.00 DYRK1A (1.00) DYRK1ABACE1BCL2PSMB5SNCA
(-)-Catechingallate SCHEMBL4639342 1.00 DYRK1A (1.00) DYRK1ABACE1BCL2PSMB5SNCA
Epicatechin Gallate SCHEMBL4639313 1.00 DYRK1A (1.00) DYRK1ABACE1BCL2PSMB5SNCA
Epicatechin Gallate SCHEMBL13014548 1.00 DYRK1A (1.00) DYRK1ABACE1BCL2PSMB5SNCA
Catechin Gallate SCHEMBL145289 1.00 DYRK1A (1.00) DYRK1ABACE1BCL2PSMB5SNCA
Epicatechin Gallate SCHEMBL4545330 1.00 DYRK1A (1.00) DYRK1ABACE1BCL2PSMB5SNCA
Epicatechin Gallate SCHEMBL8426343 1.00 DYRK1A (1.00) DYRK1ABACE1BCL2PSMB5SNCA
Epicatechin Gallate SCHEMBL31297152 1.00 DYRK1A (1.00) DYRK1ABACE1BCL2PSMB5SNCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122042866-A Method for separating, detecting and identifying flavonoid component in cocoa 中国热带农业科学院香料饮料研究所 2026-05-15 CN claimed
US-20260130395-A1 Water Dispersible Botanical Compositions AQUILA BLACK LTD (AU) 2026-05-14 US claimed
WO-2026087667-A1 METHOD OF MODIFICATION OF WHEY PROTEIN AT ACIDIC PH BY REACTION WITH OXIDIZED PHENOLIC COMPOUNDS, THE MODIFIED PROTEIN COMPOSITION, AND NUTRITIONAL USES OF THE MODIFIED PROTEIN COMPOSITION ARLA FOODS AMBA (DK) 2026-04-30 WO claimed
EP-3346842-B1 STABLE INOCULANT COMPOSITIONS AND METHODS FOR PRODUCING SAME NOVONESIS PLANT BIOSOLUTIONS AS (DK) 2026-03-25 EP claimed
EP-4697979-A1 METHOD OF PRODUCING A MODIFIED PROTEIN COMPOSITION BY REACTION WITH OXIDIZED PHENOLIC COMPOUNDS, THE MODIFIED PROTEIN COMPOSITION, AND NUTRITIONAL USES OF THE MODIFIED PROTEIN COMPOSITION Arla Foods amba (DK) 2026-02-25 EP claimed
EP-4687495-A2 GRAPE SEED EXTRACTS AND RELATED SYSTEMS AND METHODS OF MANUFACTURE E. & J. Gallo Winery (US) 2026-02-11 EP claimed
EP-4340640-B1 HIGH PROTEIN, MICELLAR CASEIN-CONTAINING NUTRITIONAL LIQUIDS ENRICHED WITH CATECHIN-COMPOUNDS AND METHOD OF PRODUCTION ARLA FOODS AMBA (DK) 2026-02-04 EP claimed
US-20260027174-A1 GRAPE SEED EXTRACTS AND RELATED METHODS OF USE GALLO WINERY E & J (US) 2026-01-29 US claimed
WO-2025201649-A1 ADVANCED NITRITE REPLACEMENT IN PROCESSED MEATS, FISH, AND DAIRY: MULTIFUNCTIONAL FOOD INGREDIENTS FOR ENHANCED PRESERVATION AND HEALTH BENEFITS NOVATICA TECHNOLOGIES LTD (GB) 2025-10-02 WO claimed
US-20250275566-A1 HIGH PROTEIN, MICELLAR CASEIN-CONTAINING NUTRITIONAL LIQUIDS ENRICHED WITH CATECHIN-COMPOUNDS AND METHOD OF PRODUCTION ARLA FOODS AMBA (DK) 2025-09-04 US claimed
EP-1861078-A2 A CAPSICUM VARIETY EXHIBITING A HYPER-ACCUMULATION OF ZEAXANTHIN AND PRODUCTS DERIVED THEREFROM Kalamazoo Holdings, Inc. (US) 2007-12-05 EP claimed
US-20070042026-A1 Prophylactic and therapeutic treatment of topical and transdermal drug-induced skin reactions MORNINGSIDE VENTURE INVESTMENTS LIMITED 2007-02-22 US claimed
US-20060185034-A1 Capsicum variety exhibiting a hyper-accumulation of zeaxanthin and products derived therefrom KALAMAZOO HOLDINGS, INC. (US) 2006-08-17 US claimed
WO-2006086706-A2 A CAPSICUM VARIETY EXHIBITING A HYPER-ACCUMULATION OF ZEAXANTHIN AND PRODUCTS DERIVED THEREFROM KALAMAZOO HOLDINGS, INC. (US) 2006-08-17 WO claimed
US-20050175565-A1 taurine and/or hypotaurine in oral formulations for preventing and treating functional disorders of the pilosebaceous unit L'OREAL (CH) 2005-08-11 US claimed
EP-1360327-A4 METHOD FOR IDENTIFYING GENES REGULATING DESIRED CELL PHENOTYPES GALILEO PHARMACEUTICALS INC (US) 2005-07-13 EP claimed
US-20040133941-A1 Methods for identifying genes regulating desired cell phenotypes BOWEN BENJAMIN A (US) 2004-07-08 US claimed
EP-1360327-A1 METHOD FOR IDENTIFYING GENES REGULATING DESIRED CELL PHENOTYPES PHYTERA, INC. (US) 2003-11-12 EP claimed
US-20030175678-A1 Methods for identifying genes regulating desired cell phenotypes GALILEO LABORATORIES, INC. 2003-09-18 US claimed
WO-2002059374-A1 METHOD FOR IDENTIFYING GENES REGULATING DESIRED CELL PHENOTYPES PHYTERA, INC. (US) 2002-08-01 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027174-A1 GRAPE SEED EXTRACTS AND RELATED METHODS OF USE MAX, VPS28, VEGFA DYRK1A 89/4885BACE1 372/4885BCL2 1855/4885
US-20260130395-A1 Water Dispersible Botanical Compositions TTPA, PNLIP, SRMS DYRK1A 1725/4885BACE1 3685/4885BCL2 194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.